The short version of phase 2 trial fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-09 and is reviewed periodically as new material appears.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Historically, PAHs contributed substantially to our understanding of adverse health effects from exposures to environmental contaminants, including chemical carcinogenesis. In 1775, Percivall Pott, a surgeon at St. Bartholomew's Hospital in London, observed that scrotal cancer was unusually common in chimney sweepers and proposed the cause as occupational exposure to soot. A century later, Richard von Volkmann reported increased skin cancers in workers of the coal tar industry of Germany, and by the early 1900s increased rates of cancer from exposure to soot and coal tar was widely accepted. In 1915, Yamigawa and Ichicawa were the first to experimentally produce cancers, specifically of the skin, by topically applying coal tar to rabbit ears. In 1922, Ernest Kennaway determined that the carcinogenic component of coal tar mixtures was an organic compound consisting of only carbon and hydrogen. This component was later linked to a characteristic fluorescent pattern that was similar but not identical to benz[a]anthracene, a PAH that was subsequently demonstrated to cause tumors. Cook, Hewett and Hieger then linked the specific spectroscopic fluorescent profile of benzo[a]pyrene to that of the carcinogenic component of coal tar, the first time that a specific compound from an environmental mixture (coal tar) was demonstrated to be carcinogenic.
Hikmat al-Hijri issued a statement demanding an urgent call for international protection, reiterating the leadership's rejection of any security force entering their areas, the General Security Service and another unidentified agency, accusing them of crossing into the province under the pretext of providing protection while bombing border villages and supporting extremist groups with heavy weaponry and drones. Shelling was reported in the neighboring Daraa Governorate, in which four civilians were wounded by a Druze group from the town of Al-Thaalah and among the villages controlled by Druze groups. Israeli aircraft were seen conducting low-altitude flights over the western countryside of Suwayda, deploying flares, the Israeli Army later announced that it had struck multiple tanks belonging to the Syrian Army in Suwayda Governorate. However a tank was repaired and was deployed again in an hour, The Syrian Arab News Agency reported a total of three Israeli strikes. On 15 July, the Syrian Minister of Defense announced that a ceasefire had been reached with Druze spiritual leadership in Suwayda to cooperate with the Interior and Defense Forces and to surrender their weapons, though it was denied by Hikmat al-Hijri who declared that he would "resist this brutal campaign by all available means", including women, children, and elderly fighting, accusing government forces of violating the ceasefire by shelling Suwayda. Israel conducted further strikes in al-Mazraa after the Syrian Armed Forces took control of the town. Strikes were also reported on the outskirts of Suwayda.
In plants, injuries result from the consumption of plant parts by herbivorous animals, including insects and mammals, from damage to tissues by plant pathogens such as bacteria and fungi, which may gain entry after herbivore damage or in other ways, and from abiotic factors such as heat, freezing, flooding, lightning, and pollutants such as ozone. Plants respond to injury by signalling that damage has occurred, secreting materials that seal off the damaged area, producing antimicrobial chemicals, and, in woody plants, regrowing over wounds.
=== Facilities at CIRB === Facilities include 20 research laboratories, livestock, frozen semen library, air-conditioned, 125-seat audio-visual seminar hall, guest house with accommodations for 25 guests. The main campus is at Hisar, with a satellite campus at Nabha in Punjab, and two regional stations in Andhra Pradesh and Gujarat respectively.
=== Cosmetic camouflage === In mild cases, vitiligo patches can be hidden with makeup or other cosmetic camouflage solutions. If the affected person is pale-skinned, the patches can be made less visible by avoiding tanning of unaffected skin.
Sources: en.wikipedia.org
== In-utero development == Vernix is produced during a distinct phase of the epidermal development. Around the 21st week of gestation, periderm cells are being shed and replaced with stratum corneum; these shedding mix with secretions of sebum by the sebaceous glands to form vernix, which gradually covers the body in an anteroposterior and dorsoventral pattern. Vernix, in itself, is also believed to aid in the formation of stratum corneum. By early third trimester, the process is complete. Soon enough, part of the vernix is emulsified by increasing concentrations of pulmonary surfactants and desiccates, only to be consumed by the fetus; a corresponding increase in amniotic fluid turbidity is noticed.
=== Disruptions to agrifood systems === Agrifood systems are exposed to shocks and stresses of various types that differ in nature and intensity, including those impair agrifood systems by disrupting the operations of related institutions, supply chains and actors. Agrifood markets are operating in an era marked by recurrent, increasingly severe and overlapping shocks, including extreme weather events, conflicts, pandemics, financial crises, disease outbreaks, and sharp increases in energy and agricultural input prices. These shocks have disrupted production, trade flows and markets, exposing vulnerabilities across food supply chains. In a highly interconnected global economy, disruptions originating in one region can rapidly propagate across borders, affecting food availability, affordability and accessibility far beyond the location of the initial shock.
Defective interfering (DI) genomes or defective viral genomes (DVGs) or defective interfering particles (DIPs) are replication defective viral RNA products generated during viral infections by many types of viruses, including SeV. It has been experimentally established that DI genomes can be readily produced by viral infection at high multiplicity. A single amino acid substitution in a nucleoprotein (NP) causes an increased production rate of DI genomes in the SeV Cantell strain, which is known for its particularly strong induction of interferon beta (IFN-β) during viral infection. It has been shown that DI are responsible for this strong IFN-β induction. Other genomic change such as loss of the Sendai virus C-protein has also been demonstrated to cause accumulation of DI genomes.
=== Synthesis === Hydrocodone is most commonly synthesized from thebaine, a constituent of opium latex from the dried poppy plant. Once thebaine is obtained, the reaction undergoes hydrogenation using a palladium catalyst.
Sources: en.wikipedia.org
Hydrocodone/paracetamol (also known as hydrocodone/acetaminophen) is the combination of the pain medications hydrocodone (an opioid) and paracetamol (acetaminophen). It is used to treat moderate to severe pain. It is taken by mouth. Recreational use is common in the United States. Common side effects include dizziness, sleepiness, constipation, and vomiting. Serious side effects include addiction, decreased rate of breathing, low blood pressure, severe allergic reactions, and liver failure. Use during pregnancy may harm the fetus. Use with alcohol is not recommended. Hydrocodone works by binding to the mu-opioid receptor. How paracetamol works is unclear but may involve blocking the creation of prostaglandins. Hydrocodone/paracetamol was approved for medical use in the United States in 1982. In the United States, it is a schedule II controlled substance. In 2023, it was the 25th most commonly prescribed medication in the United States, with more than 21 million prescriptions. It is not available in the United Kingdom, though the combination codeine/paracetamol (co-codamol) is. It is sold under the brand names Vicodin and Norco among others.
== Occurrence == After its discovery in elastic tendons in dragon flies and wing hinges in locusts, resilin has been found in many structures and organs in arthropods. Resilin is often found as a composite with chitin in insect cuticle, where chitin serves as the structural component. Resilin provides elasticity and possibly other properties. It has been discovered in the salivary pump of assassin bugs (Rhodnius prolixus), tsetse flies, and honey bees, and in the resistance providing mechanism for the venom-dispensing pump of honey bee stingers. Resilin has also been found in the sound production organs of arthropods, such as cicadas and the moth family Pyralidae, where both high elasticity and high resilience of resilin play important roles due to the rapid stress-release cycles of sound-producing tymbals. Besides these structures, resilin exists most widely in the locomotion systems of arthropods. It was discovered in wing hinges to enable recovery from deformation of wing elements, and to dampen the aerodynamic forces felt by the wing; in ambulatory systems of cockroaches and flies to facilitate rapid joint deformation; in jumping mechanisms, resilin stores kinetic energy with great efficiency and releases it upon unloading. It is also abundant in the cuticle surrounding the abdomens of termites, ants, and bees, which expand and swell to a great extent during feeding and reproduction process.
Hirschey, Matthew D.; Shimazu, Tadahiro; Goetzman, Eric; Jing, Enxuan; Schwer, Bjoern; Lombard, David B.; Grueter, Carrie A.; Harris, Charles; Biddinger, Sudha (2010-03-04). "SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation". Nature. 464 (7285): 121–125. Bibcode:2010Natur.464..121H. doi:10.1038/nature08778. ISSN 1476-4687. PMC 2841477. PMID 20203611.
While the chain has grown nationwide, both of its two outlets in North Queensland closed in November 2022, which were previously locations in Cairns and Townsville. In April 2025, Taco Bell owner Collins Foods announced to exit the Australian operations, with the prospect of finding a buyer in 12 months or else winding up the business. In March 2026, just weeks from the deadline, Collins Foods successfully transferred the operations to Restaurant Brands, another partner in the area. 6 stores will close in Queensland and 1 in Victoria, leaving 20 in the deal but saving the company from demise and a more exorbitant closure.
==== Liver ==== (help wikipedia by contributing to this subsection) Glycogenosis-like phenotype of congenital hyperinsulinism due to HNF4A mutation or MODY1 (maturity-onset diabetes of the young, type 1). This phenotype of MODY1 has macrosomia and infantile-onset hyperinsulinemic hypoglycemia, physiological 3-OH butyrate, increased triglyceride serum levels, increased level of glycogen in liver and erythrocytes, increased liver transaminases, transient hepatomegaly, renal Fanconi syndrome, and later develop liver cirrhosis, decreased succinate-dependent respiration (mitochondrial dysfunction), rickets, nephrocalcinosis, chronic kidney disease, and diabetes.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.